Genprex Moving Toward Public Share Listing

News provided by

Mar 23, 2016, 09:00 ET

AUSTIN, Texas, March 23, 2016 /PRNewswire/ -- Genprex, Inc. announced today that it has signed a Pre IPO-M Management Services Agreement with Devcap Partners, LLC. in preparation for Genprex's shares becoming publicly traded. The Agreement contemplates that Genprex's shares will initially be listed on a national market quotation system in the second quarter of 2016, and that the Company will subsequently conduct a public offering of its securities.

About Genprex: Genprex, Inc., based in Austin, Texas, is a clinical stage biopharmaceutical company founded to bridge critical gaps in the cancer therapeutics sector by developing products to unlock the potential of proven but limited cancer drugs. The Company is working to expand clinical populations benefitting from currently approved therapies by using them in combination with its biologic agents to promote genome-wide applications of the combination therapy and to participate in expanding proven markets. Clinical and pre-clinical evidence indicates that Genprex's lead drug candidate, Oncoprex, is synergistic with EGFR inhibitors such as Tarceva; and may enable non-EGFR mutant non-small cell lung cancer patients who currently are not expected to benefit from Tarceva, to receive and benefit from Tarceva and other EGFR inhibitors. This non-EGFR mutant population represents approximately 85 percent of non-small cell lung cancer patients; thus Oncoprex may significantly expand the population of lung cancer patients who benefit from Tarceva and other EGFR inhibitors.

Genprex works with world-class institutions and collaborators to in-license and develop drug candidates and controls 16 issued and 9 pending patents. Genprex is currently conducting a Phase I/II clinical trial of its Oncoprex FUS1/TUSC2 therapy in combination with Tarceva in non-small cell lung cancer.

Editor's Note: Tarceva^® is a registered trademark of the Roche Group including Genentech and Chugai and Astellas Pharma.